spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Orion Corporation 

 HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2016
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2014
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2014
Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment - Orion upgrades full-year outlook for 2014
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2013
Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2013
Mylan Announces STALEVO(R) Settlement Agreement
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 17 Feb 2009
Newly Published Menopause Study: 'Bioidentical' and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 3 Mar 2008
GTx Announces Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
FDA Approves Divigel(R) (estradiol gel) 0.1 Percent for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
Biopharmaceuticals Drug Delivery FDA
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Orion Corporation
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!